XXXX augments the renal response to an @entity535 infusion in @entity6 adults.

@entity1 @entity6 @entity10945 @entity535 @entity3371 @entity8045 @entity1723
This study examined whether @entity1 with @entity1723 and normal renal function have an altered response to an @entity535 infusion when they are pretreated with a converting-enzyme inhibitor. Three groups of adults received @entity535 infusions for 20 min on two occasions separated by a 240-min interval. Groups 1 (6 normals) and 2 (6 diabetics) ingested @entity3371 (12.5 mg) 120 min before starting the second infusion. Group 3 (4 diabetics) did not receive @entity3371 . Diabetics had normal base-line renal plasma flow, as indicated by @entity10945 clearance ( @entity8045 ), and glomerular filtration rate (GFR). In group 1, the maximum increase in @entity8045 was significant and similar with both infusions, 23 +/- 5 vs. 15 +/- 3% (SE); maximal changes in GFR were also significant and similar, 20 +/- 5 vs. 20 +/- 6%. In Group 2, the maximal increase in @entity8045 and GFR with the first infusion was 28 +/- 7 and 23 +/- 6%, respectively. After @entity3371 , the increases in @entity8045 and GFR were significantly greater than with the first infusion (64 +/- 8%, P less than 0.002, and 67 +/- 9%, P less than 0.002, respectively). In Group 3 diabetics, there was no difference in either @entity8045 or GFR with the first vs. the second infusion. Thus @entity3371 enhances the renal hemodynamic response to an @entity535 load in @entity6 @entity1 but not in normal adults.
